Skip to main content
OpenTrials
Completed

NCT Number: NCT00715793

Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma

The combination of TMZ and DAC may effect dual modulation of DNA repair genes resulting in improved clinical response.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Malignant Melanoma Melanoma Neoplasm Metastasis Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Germ Cell and Embryonal Neoplasms, Nerve Tissue Neoplastic Processes Neuroectodermal Tumors Neuroendocrine Tumors Nevi and Melanomas Pathologic Processes Pathological Conditions, Signs and Symptoms Skin Diseases Skin Neoplasms Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

UPMC Cancer Centers

Pittsburgh, Pennsylvania, 15232, United States

About this study

Primary Objectives:

  • Phase I: To determine the safety, tolerability, and Phase II recommended dose of the combination of extended schedule TMZ and DAC.
  • Phase II: To determine the efficacy, as measured by overall response rate, of the combination of extended schedule TMZ and DAC given at the Phase II recommended dose to patients with metastatic melanoma.

Secondary Objectives:

  • To determine pharmacokinetics of the combination of TMZ and DAC in patients with metastatic melanoma.
  • To determine, in peripheral blood mononuclear cells (PBMC) and tumor tissue, the pharmacodynamic effects of the combination of TMZ and DAC on promoter methylation and expression of selected genes and correlate these with response.
  • To determine the progression-free survival of patients treated with the combination of TMZ and DAC.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients who have non-resectable Stage IIIB or stage IV metastatic melanoma that have progressed despite prior therapies.
  • Life expectancy of at least 12 weeks.
  • ECOG performance status of 0, 1 and 2.
  • ≥18 years of age.
  • Patients who have not received any other chemotherapeutic, biological or investigational agent within 28 days of study drug administration.
  • First line and active brain metastases (metastatic lesions to the brain that have been adequately treated with surgery and/or appropriate radiation therapy and that have documented stability for >4 weeks or >2 weeks if treated with stereotactic radiosurgery, remain eligible)

Exclusion criteria

  • Any evidence of renal dysfunction (proteinuria, estimated creatinine clearance from serum creatinine test of <60 ml/min).
  • Impaired hepatic function (liver enzymes greater than twice the upper limit of normal or bilirubin > 2.0 except in patients with Gilbert's syndrome).
  • Prior treatment with alkylating agents (including TMZ and DTIC).
  • Active brain metastases (metastatic lesions to the brain that have been adequately treated with surgery and/or appropriate radiation therapy and that have documented stability for >4 weeks remain eligible).
  • Active infections or serious general medical conditions.
  • Female patients of child-bearing age who are not on adequate contraception, or are pregnant or breast-feeding.

Treatment and study plan

decitabine

Drug

In Part I patients will be treated on a standard "3+3" phase I dose-escalation design starting at 0.075 mg/kg until a decitabine dose level of 0.15 mg/kg is reached, or, in case unacceptable toxicities are observed, at the maximum tolerated dose (Phase II recommended dose). Decitabine will be administered at the specified dose level, intravenously, daily 5 days a week for the first 2 weeks of a 6-week cycle.

Other names: DTIC

Temozolomide

Drug

Temozolomide is available in 25 mg and 100 mg tablets that will be administered orally; doses will be rounded to the nearest 25 mg. Temozolomide will be administered orally at 75 mg/m2 daily for 4 weeks starting on week 2 of a 6-week cycle.

Other names: TMZ

Biopsy

Procedure

Fine needle aspirates (FNA) and/or core biopsies of tumor samples will be obtained from consenting patients with accessible, evaluable disease, on days 1, 8, 15, and 29 of the first cycle and when patients go off study. Biopsies are optional in Phase I and required for all consenting subjects in Phase II.

Other names: fine needle aspirate, FNA, core biopsy

Primary outcomes

  1. Percentage of Participants That Experienced a Dose Limiting Toxicity (DLT)

    Time frame: Up to 26 months

    Dose-limiting toxicities (DLTs) were defined as grade 4 neutropenia or thrombocytopenia which lasts >7 days; grade 3 or 4 febrile neutropenia; grade 3 or greater non-hematological toxic effects.

  2. Overall Response Rate (ORR)

    Time frame: Up to 30 months

    Using RECIST v1.0 criteria, overall response rate (ORR) was determined by the number of participants with complete response (CR) + the number of participants with partial response (PR) / the number of participants with complete response (CR) + the number of participants with partial response (PR) + the number of participants with stable disease (SD) + the number of participants with progressive disease (PD), multiplied by 100. Per RECIST v1.0 criteria (assessed by MRI or CT): Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for a Partial Response (PR) nor sufficient increase to to qualify for Progressive Disease (PD); PD, 20% increase in the sum if target lesion or the appearance of new lesions; Complete Response (CR), Disappearance of all target lesions.

  3. Recommended Phase 2 Dose (RP2D) of DAC + TMZ

    Time frame: Up to 26 months

    Toxicity assessments used CTCAE v3.0. Two dose levels were explored in the phase I portion of the study. A modified 3 + 3 'up and down' design was used. Given the knowledge that DAC exhibits its epigenetic effects at 30-fold lower doses than at its maximum-tolerated dose (MTD), escalation of DAC to the MTD was not done.

Secondary outcomes

  1. Disease Control Rate (DCR)

    Time frame: Up to 30 months

    Using RECIST v1.0 criteria, disease control rate (DCR) was determined by the number of participants with complete response (CR) + the number of participants with partial response (PR) + the number of participants with stable disease (SD) / the number of participants with complete response (CR) + the number of participants with partial response (PR) + the number of participants with stable disease (SD) + the number of participants with progressive disease (PD). Per RECIST v1.0 criteria (assessed by MRI or CT): Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for a Partial Response (PR) nor sufficient increase to to qualify for Progressive Disease (PD); PD, 20% increase in the sum if target lesion or the appearance of new lesions; Complete Response (CR), Disappearance of all target lesions.

  2. Progression-free Survival (PFS)

    Time frame: Up to 42 months

    PFS was defined as the time from study entry until the documented radiological or symptomatic progression. Per RECIST v1.0 criteria (assessed by MRI or CT): Progressive Disease (PD); PD, 20% increase in the sum if target lesion or the appearance of new lesions.

  3. 6-month Progression-free Survival (PFS) Rate

    Time frame: 6 months

  4. Overall Survival (OS)

    Time frame: Up to 42 months

    OS was defined as the time from study entry until the death or date of last contract.

  5. 1-year Overall Survival (OS) Rate

    Time frame: 12 months

    Percentage of patients alive at one year (number of patients alive / total number of evaluable (analyzed) patients).

Sponsors and collaborators

Lead sponsor

Hussein Tawbi

Other

Collaborators

  • Eisai Inc.
  • Schering-Plough

Registry information

Official study title

Phase I/II Trial of the Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma

Acronym: UPCI-07-008

Important dates

Study start
2008
Primary completion
2015
Study completion
2015
First posted
Jul 15, 2008
Registry last updated
Oct 3, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.